Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.

ABSTRACT: The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil(®), the first nanomedicine approved by the US Food and Drug Administration, with free doxorubicin did not find an actual translation of the EPR effect into a statistically significant increase in overall survival but did show less cardiotoxicity. In the current work, we used a two-factor factorial experimental design with intraperitoneal versus intravenous delivery and nanomedicine versus free drug as factors to test our hypothesis that regional (intraperitoneal) delivery of nanomedicine may better increase survival when compared with systemic delivery. In this st

SUBMITTER: Shen YA 

PROVIDER: S-EPMC4386769 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature